-
-
-
-
-
-
-
Roivant Sciences Ltd. (ROIV) Tops Q4 EPS by 57c
-
-
-
-
-
-
-
After-hours movers: Moderna, CrowdStrike, Ross Stores, Box and more
-
-
-
-
-
-
-
Roivant Sciences Ltd. (ROIV) Misses Q3 EPS by 7c
-
-
-
-
-
-
-
Roivant Sciences (ROIV) PT Raised to $29 at Leerink Partners
-
-
-
-
-
-
-
Goldman Sachs Reiterates Buy Rating on Roivant Sciences (ROIV)
-
-
-
-
-
-
-
Pulmovant receives orphan drug status in Japan for lung disease treatment
-
-
-
-
-
-
-
Roivant Sciences authorizes $500 million share repurchase program
-
439,043 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

